Value-Based Cancer Care Issues


October 2014, Vol 5 , No 8

New Mexico Oncology Medical Home

Cancer Center Profile

Cancer care has been undergoing transformation in recent years. The oncology medical home is one model that has shown improved outcomes and patient satisfaction. What are the characteristics of the oncology medical home and how is it different from other cancer centers in the United States? Value-Based Cancer Care (VBCC) discussed these questions with Barbara L. McAneny, MD, CEO, New Mexico Oncology Hematology Consultants, who established the New Mexico Cancer Center’s Oncology Medical Home as part of the COME HOME award from the Center for Medicare and Medicaid Innovation. [ Read More ]

Patient-Centered Oncology Medical Home Improves Health Outcomes at Lower Costs to Patients and Payers

Wayne Kuznar

AVBCC 2014 4th Annual Conference

Los Angeles, CA—Oncology practices are evolving in an era of cost containment and a renewed focus on quality. At the Fourth Annual Conference of the Association for Value-Based Cancer Care, John D. Sprandio, MD, Chief of Medical Oncology and Hematology at Oncology Management Services, Ltd, a single-specialty practice transformation company, discussed how his Pennsylvania-based integrated care delivery model has evolved to meet the parallel needs of oncology payers and patients with cancer. [ Read More ]

Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab – Dual HER2 blockade a new standard of care

Phoebe Starr

ESMO 2014 Highlights

Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with HER2-positive metastatic breast cancer. [ Read More ]

Value Propositions – October 2014

Value Propositions

Medicare Begins Coverage of Only FDA-Approved Noninvasive Stool DNA Test for Colorectal Cancer
NCI Launches Study of Exceptional Responders to Cancer Therapies: A New Phase in Precision Medicine?
New Collaboration on Novel Immunotherapy Vaccine May Revolutionize Lung Cancer Treatment
Mechanism of Action of Low-Dose Aspirin in Reducing Cancer Mortality Identified [ Read More ]

PD-1–Blocking Nivolumab Shows Impressive Responses in Melanoma

Phoebe Starr

ESMO 2014 Highlights

Madrid, Spain—Immunotherapy marches on, showing continued progress in treating advanced melanoma. At the 2014 European Society for Medical Oncology (ESMO) Congress, first reports from a phase 3 clinical trial showed that the monoclonal anti–PD-1 antibody nivolumab achieved superior responses and longer progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in the second- or third-line treatment of patients whose melanoma progressed with ipilimumab therapy. [ Read More ]

Mixed Results with Postprogression EGFR Inhibition in Advanced Non–Small-Cell Lung Cancer

Charles Bankhead

ESMO 2014 Highlights

Madrid, Spain—Continuing an EGFR inhibitor after acquired resistance does not slow the progression of advanced non–small-cell lung cancer (NSCLC) in patients receiving chemotherapy, according to a report presented at the 2014 European Society for Medical Oncology (ESMO) Congress. However, extending anti-EGFR therapy with erlotinib beyond disease progression may be beneficial, according to a second report presented at the meeting. [ Read More ]

HHS Relaxes Electronic Health Record Certification Criteria

Rosemary Frei, MSc

Health Policy

The US Department of Health and Human Services (HHS) has responded to the chorus of voices calling for less complex rules governing electronic health records (EHRs) by not adopting the Voluntary 2015 Edition Electronic Health Record Certification Criteria. In its final rule, released in September 2014, the Office of the National Coordinator for Health Information Technology has instead included 10 optional and 2 revised certification criteria. [ Read More ]

HER2-Derived Vaccine Cuts Recurrences in Patients with High-Risk Breast Cancer

Wayne Kuznar

Breast Cancer

San Francisco, CA—A new GP2 peptide vaccine was safe and reduced the rate of breast cancer recurrence in women with high-risk breast cancer in a phase 2 clinical trial. The vaccine was particularly effective in reducing recurrence in women with HER2 overexpression, reported Elizabeth A. Mittendorf, MD, PhD, Assistant Professor of Surgical Oncology, M.D. Anderson Cancer Center, Houston, at the 2014 Breast Cancer Symposium. [ Read More ]

Adding Luteinizing Hormone-Releasing Hormone Agonist to Chemotherapy Preserves Fertility in Women with Breast Cancer

Wayne Kuznar

Breast Cancer

San Francisco, CA—A second study adds to the body of evidence that including a luteinizing hormone-releasing hormone (LHRH) agonist with chemotherapy as treatment for breast cancer increases a younger woman’s likelihood of becoming pregnant. The new data, which were presented at the 2014 Breast Cancer Symposium, come from a long-term follow-up of the phase 3 clinical trial known as PROMISE-GIM6. [ Read More ]

Study Identifies Important Benefits of Cancer Survivorship Programs

Charles Bankhead

Breast Cancer

San Francisco, CA—Patients with breast cancer who attended survivorship clinics demonstrated improved compliance with follow-up visits, increased use of supportive services, and felt their concerns were better addressed, according to the results of a cancer center’s patient survey reported by Leah L. Dietrich, MD, an oncologist at Gundersen Health System, La Crosse, WI, at the 2014 Breast Cancer Symposium. [ Read More ]

Multigene Test Stratifies Prostate Cancer Aggressiveness

Rosemary Frei, MSc

Prostate Cancer

Chicago, IL—The commercially available cell-cycle progression test known as Prolaris is helpful for stratifying risk for men with clinically localized prostate cancer and can help to modify treatment decisions for men with prostate cancer based on the aggressive nature of their tumor, according to a poster presented at the 2014 College of American Pathologists annual meeting by Michael K. Brawer, MD, Vice President of Medical Affairs, Urology, Myriad Genetic Laboratories, Inc, Salt Lake City, UT, and colleagues. [ Read More ]

In The Literature – October 2014

In the Literature

PIK3CA Mutations Associated with Favorable Prognostic Factors in Breast Cancer
Coexistence of BRAF and TERT Mutations Identified in Papillary Thyroid Cancer
Novel Mutations Identified Can Help to Overcome Treatment Resistance in Lung Cancer [ Read More ]

IOM’s Call to Action on End-of-Life Care in the United States

Laura Morgan

End-of-Life Care

The initiative to improve end-of-life care in the United States is taking center stage, and it is about time. The US population is aging, and the number of older Americans with comorbidities is growing. In addition, the US population is becoming more culturally diverse, so there is an increased need for more responsive, patient-centered care. Furthermore, the current healthcare system is disjointed, and contains elements that obstruct the delivery of high-quality end-of-life care, according to a new report. [ Read More ]

Does Comparative Effectiveness Research Have Value in Oncology?

Wayne Kuznar

AVBCC 2014 4th Annual Conference

Los Angeles, CA—Can comparative effectiveness research (CER) be used for determining value in cancer care? At the Fourth Annual Conference of the Association for Value-Based Cancer Care, C. Daniel Mullins, PhD, Chairman, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, discussed this topic (see also article in the September issue of this journal) on the challenges of applying CER into value-based oncology therapy. [ Read More ]

Managing Cancer at the Workplace Enhances Productivity, Has Value for Employers

Wayne Kuznar

AVBCC 2014 4th Annual Conference

Los Angeles, CA—It is a good business decision to invest in better cancer management for employees with cancer, according to Lillie D. Shockney, RN, MAS, University Distinguished Service Associate Professor of Breast Cancer, Johns Hopkins Breast Center. This type of effort can maximize the productivity of employees with cancer or cancer survivors and reduce the work-related impact on coworkers, said Ms Shockney at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]

Medicaid Reimbursement Rate Has Direct Impact on Cancer Screening Rates

Rosemary Frei, MSc

Economics of Cancer Care

Although increasing the reimbursement rate for cancer screening tests does not consistently improve the likelihood of Medicaid beneficiaries being screened for cancer, raising the rate of reimbursement for office visits does consistently increase the likelihood that they will be screened for cancer, including breast or prostate cancer, according to results of a new analysis of Medicaid claims and enrollment data. [ Read More ]

CLEOPATRA: Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab

Phoebe Starr

ESMO 2014 Highlights

Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with HER2-positive metastatic breast cancer. This should become the new standard of care for patients with metastatic HER2 disease, according to the study investigators, who presented their results at the 2014 European Society for Medical Oncology (ESMO) Congress. [ Read More ]